Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.
| Revenue (Most Recent Fiscal Year) | $7.53M |
| Net Income (Most Recent Fiscal Year) | $-526.24M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 920.63 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -6988.63% |
| Net Margin (Trailing 12 Months) | -6988.63% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -65.08% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.12 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.12 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-3.94 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.38 |
| Earnings per Share (Most Recent Fiscal Year) | $-5.45 |
| Diluted Earnings per Share (Trailing 12 Months) | $-5.45 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 104.58M |
| Free Float | 101.02M |
| Market Capitalization | $6.93B |
| Average Volume (Last 20 Days) | 1.26M |
| Beta (Past 60 Months) | 0.68 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.40% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |